Collaborations and License Agreements - Additional Information (Detail)	1 Months Ended								3 Months Ended								12 Months Ended
	Apr. 30, 2016 USD ($)	Sep. 30, 2015 USD ($)	Aug. 31, 2015 USD ($)	Nov. 30, 2014 USD ($)	Mar. 31, 2014 USD ($)	Dec. 31, 2012 USD ($)	Mar. 31, 2010 USD ($)	Dec. 31, 2006 USD ($)	Dec. 31, 2016 USD ($)	Sep. 30, 2016 USD ($)	Jun. 30, 2016 USD ($)	Mar. 31, 2016 USD ($)	Dec. 31, 2015 USD ($)	Sep. 30, 2015 USD ($)	Jun. 30, 2015 USD ($)	Mar. 31, 2015 USD ($)	Dec. 31, 2016 USD ($) Indication	Dec. 31, 2015 USD ($)	Dec. 31, 2014 USD ($)	Dec. 31, 2011 USD ($)	Oct. 14, 2016	Apr. 30, 2014 USD ($)
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaboration revenue									$ 127,000	$ 992,000	$ 193,000	$ 1,203,000	$ 3,598,000	$ 15,158,000	$ 134,000	$ 134,000	$ 2,515,000	$ 19,024,000	$ 18,123,000
Amounts due from pursuant to the cost-sharing provisions									$ 1,027,000				4,641,000				1,027,000	4,641,000
Research and development																	23,703,000	12,875,000	38,254,000
Credited against amounts due the Company for tenant improvements
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Development and sales-based milestones payment																	22,500,000
Will be paid in nine equal monthly installments
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Development and sales-based milestones payment																	5,500,000
Scenario 3
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Development and sales-based milestones payment																	4,200,000
Sales Based Milestone Payments
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaborations and license agreements, expected milestone receivable																	0
Other License Agreements
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Research and development																	25,000
License payment per product																	1,000,000
License expense																	$ 0	0	0
Other License Agreements | Maximum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaborations and license agreements, royalties payment on net sales									1.50%								1.50%
Other License Agreements | Minimum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaborations and license agreements, royalties payment on net sales									0.50%								0.50%
CANbridge
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
License agreement date																	Mar. 16, 2016
Collaborations and license agreements, milestone payment received																	$ 0
CANbridge | Licensing Agreements
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaborations and license agreements, expected milestone receivable	$ 1,000,000																1,000,000
Upfront payment, withholding taxes																	100,000
Reimbursable amount for manufacturing costs and expenses.																	$ 1,000,000
Collaborations and license agreements, time period from first commercial sale of certain product upon which the agreement expires																	10 years
Allocation of upfront payment																	$ 1,000,000
Collaboration revenue																	1,000,000
CANbridge | Licensing Agreements | Sales Based Milestone Payments
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaborations and license agreements, expected milestone receivable																	90,000,000
CANbridge | Licensing Agreements | Development and Regulatory Milestone Events
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaborations and license agreements, expected milestone receivable																	42,000,000
CANbridge | Licensing Agreements | Due Within Twelve Months From Effective Date
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Reimbursable amount for manufacturing costs and expenses.																	500,000
CANbridge | Licensing Agreements | Due Within Eighteen Months From Effective Date
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Reimbursable amount for manufacturing costs and expenses.																	$ 500,000
EUSA
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
License agreement date																	Dec. 21, 2006
Collaborations and license agreements, expected milestone receivable																	$ 4,000,000
Research and development funding received																	2,500,000	2,500,000
Payments received in connection with indications																	$ 2,000,000
Eligible number of indications | Indication																	3
Payments received in connection with additional indications																	$ 5,000,000
Potential payments received in connection with additional indications																	335,000,000
Collaborations and license agreements, milestone payment received																	400,000	14,000
EUSA | Utilization of Data Generated by Planned Phase Three Study
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Milestone payment to be received									$ 20,000,000								20,000,000
EUSA | Phase One Combination Study
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Milestone payment to be received									2,000,000								2,000,000
EUSA | Marketing Approval in France, Germany, Italy, Spain and the United Kingdom
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Milestone payment to be received									2,000,000								2,000,000
EUSA | Marketing Approval in Argentina, Australia, Brazil, South Africa and Venezuela
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Milestone payment to be received									2,000,000								2,000,000
Novartis
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaborations and license agreements, expected milestone receivable		$ 15,000,000
Collaborations and license agreements, milestone payment received																	0
Reimbursable inventory			$ 3,500,000
License and service revenue												3,500,000
Novartis | Sales Based Milestone Payments
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaborations and license agreements, expected milestone receivable																	150,000,000
Novartis | Clinical Efficacy Milestone
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaborations and license agreements, expected milestone receivable																	53,000,000
Novartis | Regulatory Milestone Events
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaborations and license agreements, expected milestone receivable																	105,000,000
Novartis | License and Technical Knowledge
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaboration revenue																		15,000,000
Pharmstandard
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Allocation of upfront payment																	1,000,000
Collaboration revenue																	900,000	61,000
Collaborations and license agreements, deferred revenue									900,000								$ 900,000
Ophthotech Corporation
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaborations and license agreements, written notice period for termination																	30 days
Ophthotech Corporation | Option and License Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaborations and license agreements, expected milestone receivable																	$ 6,000,000
Upfront license payment				$ 500,000
Collaborations and license agreements, payment received																			500,000
Collaborations and license agreements, revenue recognized																	100,000	200,000	38,000
Remaining deferred revenue to be recognized																	100,000
Biodesix
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Amounts due from pursuant to the cost-sharing provisions									800,000								800,000
Biodesix | FOCAL study
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Contribution percentage of clinical, regulatory, manufacturing and other costs																						50.00%
Percentage of closeout project cost																					50.00%
Biodesix | FOCAL study | Maximum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Funding																						$ 15,000,000
Biodesix | FOCAL trial
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaborations and license agreements, royalties payment on net sales																						10.00%
Amounts due from pursuant to the cost-sharing provisions									800,000				1,100,000				800,000	1,100,000
Cash received related to cost reimbursements																	2,800,000	4,200,000
Biodesix | FOCAL trial | Research and development
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Payments received and recorded as an increased (decreased) to expense pursuant to cost-sharing provisions																	2,500,000	3,500,000	2,700,000
Astellas Pharma Inc. | Astellas Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Amounts due from pursuant to the cost-sharing provisions									$ 100,000				$ 100,000				100,000	100,000
Astellas Pharma Inc. | Astellas Agreement | Research and development
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Payments received and recorded as an increased (decreased) to expense pursuant to cost-sharing provisions																	300,000	700,000	3,500,000
Astellas Pharma Inc. | Collaboration and License Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaborations and license agreements, payment received																	300,000	1,500,000	4,100,000
Biogen Idec International GmbH
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaborations and license agreements, deferred revenue					$ 14,700,000
Collaborations and license agreements, revenue recognized					14,100,000
Collaborations and license agreements, relative selling price of the deliverable					$ 600,000
Biogen Idec International GmbH | Maximum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Royalty payments																	50,000,000
Biogen Idec International GmbH | Option and License Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaborations and license agreements, revenue recognized																	$ 38,000	$ 300,000	$ 14,500,000
St Vincent's Hospital Sydney Limited
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Amendment agreement date																	2015-08
License fees payable												$ 18,900,000
Collaborations and license agreements, milestone payment																	$ 400,000
St Vincent's Hospital Sydney Limited | Licensing Agreements | Up-front Payment Arrangement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaborations and license agreements, cash payment																	$ 1,500,000
Kyowa Hakko Kirin | Utilization of Data Generated by Planned Phase Three Study | Maximum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Research and development reimbursement payment not required to be paid								$ 20,000,000
Kyowa Hakko Kirin | Phase One Combination Study | Maximum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Research and development reimbursement payment not required to be paid								2,000,000
Kyowa Hakko Kirin | Licensing Agreements
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaborations and license agreements, cash payment								5,000,000
Collaborations and license agreements, milestone payment							$ 10,000,000
Collaborations and license agreements, potential future milestone payments, maximum amount								$ 18,000,000
Collaborations and license agreements, potential future payment as percentage of certain amounts the Company receives under sublicense agreements								30.00%
Reimbursement of Research and development milestone								$ 4,000,000
Term of royalty payment obligations								12 years
Kyowa Hakko Kirin | Licensing Agreements | FDA Marketing Approval
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaborations and license agreements, milestone payment						$ 12,000,000
Kyowa Hakko Kirin | Collaboration and License Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaborations and license agreements, up-front license payment received																				$ 22,500,000